Harnessing Innate and Adaptive Immune Responses to Cure Disease
Building upon the long-standing observation of tumor regression in the setting of bacterial infection, we have developed a unique and patented approach designed to exploit bacteria’s natural ability to fully engage the human immune system and cure disease. Our novel insights have enabled us to create proprietary, attenuated and killed non-pathogenic gram-negative bacteria that have demonstrated broad anti-tumor and anti-viral activity in pre-clinical models to date.
Latest Press Release
May 12, 2022
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK (May 12, 2022) – Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for read more →